Active-site-directed specific competitive inhibitors of phospholipase A2: novel transition-state analogues.
More than 100 amphiphilic phosphoesters, possible tetrahedral transition-state analogues capable of coordinating to the calcium ion at the active site of phospholipase A2, were designed, synthesized, and tested as inhibitors for the hydrolysis of 1,2-dimyristoyl-sn-glycero-3-phosphomethanol vesicles in the scooting mode. This assay system permits the study of structurally diverse inhibitors with phospholipase A2S from different sources, and it is not perturbed by factors that change the quality of the interface. As a prototype, 1-hexadecyl-3-trifluoroethylglycero-2-phosphomethanol (MJ33) was investigated in detail. Only the (S)-(+) analogue of MJ33 is inhibitory, and it is as effective as the sn-2 phosphonate or the sn-2 amide analogues of sn-3 phospholipids. The inhibitory potencies of the various phosphoesters depended strongly on the stereochemical and structural features, and the mole fractions of inhibitors required for 50% inhibition, X1(50), ranged from more than 1 to less than 0.001 mole fraction. The affinity of certain inhibitors for enzymes from different sources differed by more than 200-fold. The inhibitors protected the catalytic site residue His-48 from alkylation in the presence of calcium but not barium as expected if the formation of the EI complex is supported only by calcium. The equilibrium dissociation constant for the inhibitor bound to the enzyme at the interface was correlated with the XI(50) values, which were different if the inhibition was monitored in the pseudo-zero-order or the first-order region of the progress curve. These results show that the inhibitors described here interfered only with the catalytic turnover by phospholipase A2's bound to the interface, their binding to the enzyme occurred through calcium, and the inhibitors did not have any effect on the dissociation of the enzyme bound to the interface.
Department of Chemistry, University of Delaware, Newark 19716.
M K
MK
Jain
W J
WJ
Tao
J
J
Rogers
C
C
Arenson
H
H
Eibl
B Z
BZ
Yu
D000818:Animals; D001667:Binding, Competitive; D002384:Catalysis; D020404:Glycerophospholipids; D006801:Humans; D008823:Micelles; D010755:Organophosphates / Q000138:chemical synthesis / Q000494:pharmacology*; D010712:Phosphatidic Acids / Q000494:pharmacology*; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000187:drug effects; D054467:Phospholipases A2; D011485:Protein Binding / Q000187:drug effects
D020404:Glycerophospholipids; D008823:Micelles; D010755:Organophosphates; D010712:Phosphatidic Acids; C029313:dimyristoylmethylphosphatidic acid; D010741:Phospholipases A; D054467:Phospholipases A2